Market Cap 792.66M
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,121,700
Avg Vol 1,108,486
Day's Range N/A - N/A
Shares Out 68.93M
Stochastic %K 35%
Beta 1.95
Analysts Strong Sell
Price Target $33.00

Company Profile

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Fax: 617 926 5050
Address:
480 Pleasant Street, Suite A-210, Watertown, United States
TA_Insights
TA_Insights Oct. 23 at 8:06 PM
$EYPT Closed strong right on the highs at $11.50 with steady buyers hitting the ask. Great sign into tomorrow momentum building.
2 · Reply
JackOtter
JackOtter Oct. 23 at 7:43 PM
$EYPT criminally undervalued. Currently largest holding and adding
1 · Reply
rizzato
rizzato Oct. 23 at 11:49 AM
$EYPT the raise was fully covered that means main shareholders or institutions added more on theirs wallet and trust on the future of the company they for sure are more informed than me and you too I'm still asking me why we we are under 12 that has no sense or just because they still have 30 days to buy more on the market price I'm pretty confident to see higher price soon even if that deep drop disturb me a lot
0 · Reply
rizzato
rizzato Oct. 22 at 7:19 PM
$EYPT George ElstonGeorge Elston • 3° e oltre3° e oltre Executive Vice President Chief Financial Officer and Head of Corporate Development at EyePointExecutive Vice President Chief Financial Officer and Head of Corporate Development at EyePoint 4 giorni • 4 giorni fa • Visibile a tutti su LinkedIn e altrove Segui This marks a major milestone for EyePoint as we announce the closing of our underwritten public offering of $150 million of shares of common stock! The net proceeds will advance our pivotal Phase 3 clinical program in DME, the second largest retinal disease market, where we currently have the only TKI in development. We appreciate the continued interest and support of our investors. As always, our mission guides every step we take.
0 · Reply
rizzato
rizzato Oct. 22 at 6:52 PM
$EYPT https://www.linkedin.com/posts/jay-s-duker-m-d-9b3ba52_eyepoint-has-announced-the-closing-of-our-activity-7385034131023372288-b95_
0 · Reply
rizzato
rizzato Oct. 22 at 6:50 PM
$EYPT View organization page for EyePoint EyePoint 16,535 followers 4d #EYPT is thrilled to announce the successful closing of our underwritten public offering of $150 million of shares of common stock. The net proceeds will enable us to advance our pivotal Phase 3 program in DME, with first patient dosing anticipated in Q1 2026. We’re proud to reach this milestone as we continue developing our innovative program.
0 · Reply
rizzato
rizzato Oct. 22 at 6:48 PM
$EYPT Jay S. Duker, M.D. 4d EyePoint has announced the closing of our underwritten public offering of $150 million of shares of common stock, marking a significant milestone in our growth journey. This financing enables us to advance our pivotal Phase 3 program in DME, an area with significant unmet need for effective, long-lasting therapies. We are currently the only company developing a TKI for this important indication. Thank you to everyone that contributed to this major achievement, including our investors, board of directors and employees. We’re proud to reach this milestone, and we remain committed to advancing our mission to improve the lives of patients with serious retinal diseases.
0 · Reply
rizzato
rizzato Oct. 22 at 6:38 PM
$EYPT could be that one the reason why we are down? In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of EyePoint’s common stock at the public offering price, less underwriting discounts and commissions.
0 · Reply
rizzato
rizzato Oct. 22 at 1:32 PM
$EYPT do you have any idea why we are dropping day by day? no more strength to overpass 12
0 · Reply
rizzato
rizzato Oct. 22 at 1:22 PM
$EYPT sound very strange no news about the raise and red again
0 · Reply
Latest News on EYPT
EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 10 days ago

EyePoint Announces Pricing of Public Offering


EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 11 days ago

EyePoint Announces Proposed Public Offering of Common Stock


EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 9 months ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference


EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 18, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024


EyePoint Is Betting The Bank On EYP-1901

Feb 21, 2024, 8:36 AM EST - 1 year ago

EyePoint Is Betting The Bank On EYP-1901


TA_Insights
TA_Insights Oct. 23 at 8:06 PM
$EYPT Closed strong right on the highs at $11.50 with steady buyers hitting the ask. Great sign into tomorrow momentum building.
2 · Reply
JackOtter
JackOtter Oct. 23 at 7:43 PM
$EYPT criminally undervalued. Currently largest holding and adding
1 · Reply
rizzato
rizzato Oct. 23 at 11:49 AM
$EYPT the raise was fully covered that means main shareholders or institutions added more on theirs wallet and trust on the future of the company they for sure are more informed than me and you too I'm still asking me why we we are under 12 that has no sense or just because they still have 30 days to buy more on the market price I'm pretty confident to see higher price soon even if that deep drop disturb me a lot
0 · Reply
rizzato
rizzato Oct. 22 at 7:19 PM
$EYPT George ElstonGeorge Elston • 3° e oltre3° e oltre Executive Vice President Chief Financial Officer and Head of Corporate Development at EyePointExecutive Vice President Chief Financial Officer and Head of Corporate Development at EyePoint 4 giorni • 4 giorni fa • Visibile a tutti su LinkedIn e altrove Segui This marks a major milestone for EyePoint as we announce the closing of our underwritten public offering of $150 million of shares of common stock! The net proceeds will advance our pivotal Phase 3 clinical program in DME, the second largest retinal disease market, where we currently have the only TKI in development. We appreciate the continued interest and support of our investors. As always, our mission guides every step we take.
0 · Reply
rizzato
rizzato Oct. 22 at 6:52 PM
$EYPT https://www.linkedin.com/posts/jay-s-duker-m-d-9b3ba52_eyepoint-has-announced-the-closing-of-our-activity-7385034131023372288-b95_
0 · Reply
rizzato
rizzato Oct. 22 at 6:50 PM
$EYPT View organization page for EyePoint EyePoint 16,535 followers 4d #EYPT is thrilled to announce the successful closing of our underwritten public offering of $150 million of shares of common stock. The net proceeds will enable us to advance our pivotal Phase 3 program in DME, with first patient dosing anticipated in Q1 2026. We’re proud to reach this milestone as we continue developing our innovative program.
0 · Reply
rizzato
rizzato Oct. 22 at 6:48 PM
$EYPT Jay S. Duker, M.D. 4d EyePoint has announced the closing of our underwritten public offering of $150 million of shares of common stock, marking a significant milestone in our growth journey. This financing enables us to advance our pivotal Phase 3 program in DME, an area with significant unmet need for effective, long-lasting therapies. We are currently the only company developing a TKI for this important indication. Thank you to everyone that contributed to this major achievement, including our investors, board of directors and employees. We’re proud to reach this milestone, and we remain committed to advancing our mission to improve the lives of patients with serious retinal diseases.
0 · Reply
rizzato
rizzato Oct. 22 at 6:38 PM
$EYPT could be that one the reason why we are down? In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of EyePoint’s common stock at the public offering price, less underwriting discounts and commissions.
0 · Reply
rizzato
rizzato Oct. 22 at 1:32 PM
$EYPT do you have any idea why we are dropping day by day? no more strength to overpass 12
0 · Reply
rizzato
rizzato Oct. 22 at 1:22 PM
$EYPT sound very strange no news about the raise and red again
0 · Reply
rizzato
rizzato Oct. 21 at 7:01 PM
$EYPT it could be interesting to understand if the main shareholders have added more
0 · Reply
rizzato
rizzato Oct. 21 at 6:44 PM
$EYPT any news about the raise ? who has increased his position?
0 · Reply
Quantumup
Quantumup Oct. 21 at 2:34 PM
RBC Capital reiterated $FDMT Outperform-$26, and said Boston NDR Strengthens Its Conviction That GTx Will Have a Role in the $15B Retina Market $OCUL $EYPT $REGN KOD $RGNX - ABBV ADVM SNY RBC Capital additionally said:
1 · Reply
rizzato
rizzato Oct. 21 at 1:53 PM
$EYPT is there any connection between the eypt red and the ocul red? they are working in a similar product any idea?
0 · Reply
rizzato
rizzato Oct. 20 at 2:31 PM
$EYPT let's try to understand the situation now: they did a raid of 150 million that was not appreciate from the market but we know that institution controls the share price they justify that saying that they will use the money to get the final result faster and come on the market as soon as possible no news are on the market but the last we got were fine in 14 days they will release the earnings and hopefully we will have the confirmation that all the situation is moving in the right direction we got a buy from mizuho securities probably that drop will be use from them to add more share and from me too the situation doesn't scare me at all but the fact that we lost 25% from the top really disturb me hopefully soon they will decide to push the price up again to reach the sky
0 · Reply
rizzato
rizzato Oct. 20 at 10:24 AM
$EYPT no news about the raise
0 · Reply
rizzato
rizzato Oct. 19 at 6:02 PM
$EYPT any news about the raise?
0 · Reply
rizzato
rizzato Oct. 17 at 5:30 PM
$EYPT Let’s see what they will let us know on November the 5th Hopefully good news
0 · Reply
rizzato
rizzato Oct. 17 at 3:34 PM
$EYPT Interesting should be to check after the raise and that drop if something is changed on the main instutution shareholder list? Did anyone found any news?
0 · Reply
rizzato
rizzato Oct. 17 at 3:05 PM
$EYPT both ocul and Eypt are still red today , any idea why?
0 · Reply
rizzato
rizzato Oct. 17 at 2:48 PM
$EYPT raise is closed but still red
0 · Reply
rizzato
rizzato Oct. 16 at 6:04 PM
$EYPT did anyone understand when the raise will be finalized?
1 · Reply